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Introduction {#ehf212243-sec-0004}
============

Sarcoidosis is a multisystem, non‐caseating granulomatous disorder of unknown aetiology, whose epidemiology underlies geographic and ethnic variations.[1](#ehf212243-bib-0001){ref-type="ref"}, [2](#ehf212243-bib-0002){ref-type="ref"} Cardiac sarcoidosis (CS) may occur isolatedly without any concurrent extracardiac presentation or in the context of multiorgan sarcoid affection. The clinical presentation of sarcoidal heart involvement is manifold and comprehends the whole range from clinically silent courses up to non‐ischaemic cardiomyopathy and conduction system defects, depending on the location of cardiac granulomatous infiltration.[3](#ehf212243-bib-0003){ref-type="ref"} Cardiac affection is described to be the second leading cause of death by sarcoidosis worldwide and the most common one in Japan.[4](#ehf212243-bib-0004){ref-type="ref"}, [5](#ehf212243-bib-0005){ref-type="ref"} In turn, up to 65% of cardiac deceases are due to sudden cardiac death in consequence of conduction blocks or malignant ventricular arrhythmias.[6](#ehf212243-bib-0006){ref-type="ref"} In keeping with this, the necessity of establishing accurate diagnostic strategies arises that allow for both feasible baseline diagnosis and follow‐up monitoring.

In a preceding, prospectively conducted trial comprising 188 patients with histologically proven sarcoidosis, we observed a prevalence of cardiovascular magnetic resonance (CMR)‐based cardiac affection of 15.4%.[7](#ehf212243-bib-0007){ref-type="ref"} In order to assess the middle‐term persistence rate of CMR findings, we presently took aim at performing longitudinal investigation of CS‐positive patients by CMR re‐examination and correlated the hereby obtained results with standard clinical testing.

Moreover, we assessed the additional insights into myocardial damage\'s characteristics gained by somatostatin receptor (SSTR) scintigraphy. As demonstrated previously,[8](#ehf212243-bib-0008){ref-type="ref"}, [9](#ehf212243-bib-0009){ref-type="ref"} receptors for somatostatin are present in the inflammatory lesions of patients with sarcoidosis and located on, e.g. granuloma epithelioid cells, macrophages, and giant cells. SSTR‐directed positron emission tomography (PET) imaging might complement CMR by visualizing the aforementioned inflammatory cell\'s distribution within damaged myocardium.[10](#ehf212243-bib-0010){ref-type="ref"} In a sub‐analysis, we, therefore, retrospectively identified patients who additionally underwent PET/computed tomography (CT) using the SSTR ligand ^68^Ga‐DOTA‐[d]{.smallcaps}‐Phe^1^‐Tyr^3^‐octreotide (^68^Ga‐DOTATOC) and correlated PET results with CMR findings and clinical parameters.

Materials and methods {#ehf212243-sec-0005}
=====================

Study population {#ehf212243-sec-0006}
----------------

We disposed of the data previously obtained by CMR imaging in 188 Caucasian patients comprising study population that was composed of patients linked to the University Hospital\'s Department of Pneumology (Bonn, Germany) and those recruited by a nationwide acting registered sarcoidosis self‐help association.[7](#ehf212243-bib-0007){ref-type="ref"} This initial examination revealed that CS was present in 29 out of 188 patients, i.e. in 15.4% of total study population. These CS‐positive patients were presently prospectively followed up by CMR re‐examination after a median period of 2.6 years. At the time of CMR re‐examination, complementary standard clinical testing by 12‐lead electrocardiogram (ECG), 24 h Holter monitoring, transthoracic echocardiography, and laboratory and pulmonary function testing was performed.

Contrary to the prospective approach of CMR re‐conduction, additional nuclear imaging by use of ^68^Ga‐DOTATOC PET/CT was performed subsequent to CMR re‐examination and only in cardiac symptomatic patients (chest pain, palpitations, dizziness, and syncopal episodes) at the discretion of the treating physician. The hereby obtained observational data on ^68^Ga‐DOTATOC PET/CT were retrospectively analysed.

The study was approved by the ethics committee of the University of Bonn and was according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all patients.

Electrocardiography {#ehf212243-sec-0007}
-------------------

A 12‐lead surface ECG was systematically obtained at the time of CMR re‐conduction. Pathological electrocardiographic findings comprehended those described to be general risk stratifiers for sudden cardiac death,[11](#ehf212243-bib-0011){ref-type="ref"} those integrated in the Heart Rhythm Society\'s (HRS\'s) expert consensus statement on the diagnosis and management of CS‐associated arrhythmias,[12](#ehf212243-bib-0012){ref-type="ref"} and those exposed in the revised Japanese Ministry of Health and Welfare Guidelines (JMHWG).[13](#ehf212243-bib-0013){ref-type="ref"}

All study participants underwent 24 h Holter monitoring, recorded by the SpiderView™ Ambulatory Electrocardiographic Recorder (SORIN GROUP, Munich, Germany). Holter ECG data were analysed for conduction block occurrence, as well as supraventricular and ventricular arrhythmic burden. Moreover, we examined heart rate variability as an established predictor of increased mortality and elevated risk of cardiac events in the general population.[14](#ehf212243-bib-0014){ref-type="ref"} T‐wave alternans that displays heterogeneity in ventricular repolarization and thus predicts ventricular arrhythmias in patients at risk for sudden cardiac death was additionally registered.[15](#ehf212243-bib-0015){ref-type="ref"} Both 12‐lead ECG and Holter recording were analysed by experienced cardiologists, blinded to the patients\' clinical background information.

Transthoracic echocardiography {#ehf212243-sec-0008}
------------------------------

In addition to CMR follow‐up, each CS‐positive patient underwent standardized two‐dimensional (2D) transthoracic echocardiography for evaluation of left and right ventricular functional parameters in accordance with the recommendations of the American Society of Echocardiography.[16](#ehf212243-bib-0016){ref-type="ref"} Standard echocardiographic views were obtained with the patient in the left lateral decubitus position in 2D and colour tissue Doppler imaging modes and by use of a commercially available ultrasound scanner (Vivid 7, General Electric Medical Health, Waukesha, WI, USA; iE 33, Philips Medical Systems, Koninklijke N.V., Hamburg, Germany). Pathological echocardiographic results were pre‐defined in line with the HRS consensus statement[12](#ehf212243-bib-0012){ref-type="ref"} and the revised JMHWG.[13](#ehf212243-bib-0013){ref-type="ref"} Accordant with electrocardiographic analysis, all echocardiographic studies were performed by versed cardiologists.

Laboratory and pulmonary function testing {#ehf212243-sec-0009}
-----------------------------------------

All CS‐positive patients underwent additional laboratory and lung function assessment at the time of CMR re‐conduction. Blood sampling comprised a full blood count and C‐reactive protein for inflammatory measurement, soluble interleukin‐2 receptor, and serum angiotensin converting enzyme for evaluation of sarcoid activity, as well as plasma N terminal pro‐brain natriuretic peptide as a biomarker for cardiac failure. In line with the European Respiratory Society\'s guidelines,[17](#ehf212243-bib-0017){ref-type="ref"} standardized pulmonary function testing comprehended spirometry, body plethysmography, and assessment of diffusing capacity for carbon monoxide.

Cardiovascular magnetic resonance imaging {#ehf212243-sec-0010}
-----------------------------------------

CMR images were acquired ECG‐gated during repeated breath‐holding on a clinical 1.5 T scanner (Intera 1.5T, Philips Healthcare, Best, The Netherlands) by use of cardiac‐dedicated phased‐array coils. The CMR protocol comprised functional imaging, T2 imaging, and assessment of relative and late gadolinium enhancement (LGE). Functional imaging was performed using steady‐state free‐precession cine sequences in short axis (SA), horizontal long axis (HLA), vertical long axis, and left ventricular outflow tract orientation. Fat‐suppressed T2‐weighted black‐blood turbo spin echo images in SA and HLA were obtained and allowed for visualization of myocardial oedema. Presence of myocardial hyperaemia as evidence of inflammatory myocardial tissue damage was detected by assessment of early relative contrast enhancement using T1‐weighted multislice imaging in transverse orientation before and immediately after injection of a single dose of extracellular contrast agent (0.1 mmol/kg gadolinium‐DTPA).[18](#ehf212243-bib-0018){ref-type="ref"} Subsequently, a second single dose of extracellular contrast agent was injected, allowing for delayed contrast enhancement imaging (detection of myocardial scars) by the use of T1‐weighted inversion‐recovery gradient echo sequence. The 17‐segment model of standardized myocardial nomenclature was applied for description of left ventricular delayed contrast enhancement distribution.[19](#ehf212243-bib-0019){ref-type="ref"} CMR studies were conducted in conformity with the recommendations on standardized CMR imaging[20](#ehf212243-bib-0020){ref-type="ref"} and independently analysed by two experienced radiologists, blinded to the patients\' clinical data. In case of discordant results, the studies were re‐assessed to reach consensus.

^68^ Ga‐DOTATOC positron emission tomography/computed tomography {#ehf212243-sec-0011}
----------------------------------------------------------------

^68^Ga‐DOTATOC, combined with high‐resolution PET and integrated CT, was employed for functional molecular cardiac imaging to assess inflammatory myocardial activity. It targets the SSTR, which has been shown to be overexpressed by activated lymphocytes, macrophages, and epithelioid cells. ^68^Ga‐DOTATOC was conducted on a Biograph 2 PET/CT scanner (Siemens Medical Solutions, Erlangen, Germany). After a mean time interval of 65.1 ± 28.0 min after intravenous administration of 2 MBq/kg ^68^Ga‐DOTATOC (mean, 118.2 ± 24.7 MBq ^68^Ga‐DOTATOC), static image acquisition was performed. Emission scans (three‐dimensional mode) were obtained of the body trunk (4 min emission time per bed position) followed by one additional bed position of the cardiac region (20 min emission time). A low‐dose CT (no intravenous contrast, 16 mA·s, 130 kV) was obtained for attenuation correction. PET data were reconstructed iteratively (AWOSEM, four iterations, eight subsets) using scatter and attenuation correction. After reconstruction, images were smoothed by a 5 mm Gaussian filter.

^68^ Ga‐DOTATOC PET/CT and CMR data were co‐registered using syngoMMWP software (version VE50A, Siemens Healthineers, Erlangen, Germany). Co‐registration was performed using an automatic rigid algorithm provided by the software, and image fusion was manually corrected by visual confirmation.

PET/CT images were analysed in a multidisciplinary setting of nuclear medicine physicians and radiologists. In case of discordance, studies were re‐assessed to reach consensus.

Statistical analysis {#ehf212243-sec-0012}
--------------------

In case of continuous variables, data were expressed as mean values ± standard deviation; categorical variables were given as total numbers and percentages. Comparison between two groups was performed by use of Mann--Whitney U‐test or Student\'s *t*‐test, as appropriate. When comparing more than two groups, the non‐parametric Kruskal--Wallis test was employed. Categorical variables were analysed by Pearson\'s χ^2^ test or Fisher\'s exact test. Correlation analysis was performed by use of Pearson correlation coefficient (Pearson\'s *r*). A two‐tailed *P*‐value of \<0.05 was considered statistically significant. Statistics were performed using SPSS software version 23.0 (Armonk, NY, USA).

Results {#ehf212243-sec-0013}
=======

Patient characteristics {#ehf212243-sec-0014}
-----------------------

Demographic and clinical characteristics of patients undergoing CMR follow‐up are specified in *Table* [1](#ehf212243-tbl-0001){ref-type="table-wrap"}. Twenty‐seven patients were prospectively enrolled and examined for persistence and degree of cardiac sarcoid affection. The total patient number diverged from the original 29 CS‐positive patients as identified by primary CMR analysis for the following reasons: two patients developed third‐degree atrioventricular block in the meantime, which required permanent pacemaker placement; of these two patients, only one patient received a CMR‐compatible device that permitted CMR re‐conduction. A further patient was excluded from follow‐up owing to renal impairment that contradicted gadolinium application.

###### 

Patient demographic and clinical characteristics at the time of cardiovascular magnetic resonance re‐conduction

  -----------------------------------------------------------------------------------------------
  All patients\                                                                    
  *n* = 27                                                                         
  -------------------------------------------------------------------------------- --------------
  Age (years)                                                                       49.9 ± 11.8

  Male gender, *n* (%)                                                               16 (59.3%)

  Organ of sarcoidosis\' histological confirmation, *n* (%)                        

  Lung                                                                               15 (55.6%)

  Lymph node                                                                         7 (25.9%)

  Skin                                                                               3 (11.1%)

  Kidney                                                                              1 (3.7%)

  Central nervous system                                                              1 (3.7%)

  Pulmonary function parameters                                                    

  FEV1 (L)                                                                           3.0 ± 1.0

  FEV1 (% predicted)                                                                92.9 ± 19.3

  RV (L)                                                                             2.1 ± 0.5

  RV (% predicted)                                                                  105.6 ± 22.1

  R tot (kPa·s/L)                                                                   0.24 ± 0.10

  R tot (% predicted)                                                               79.2 ± 35.1

  IVC (L)                                                                            3.9 ± 1.2

  IVC (% predicted)                                                                 94.4 ± 15.8

  TLC (L)                                                                            6.0 ± 1.3

  TLC (% predicted)                                                                 96.0 ± 11.5

  DLco (mmol/min/kPa)                                                                7.0 ± 2.2

  DLco (% predicted)                                                                72.6 ± 15.4

  DLco/VA (mmol/min/kPa/L)                                                           1.4 ± 0.2

  DLco/VA (% predicted)                                                             88.6 ± 14.2

  Capillary blood gas analysis                                                     

  pO~2~ (mmHg)                                                                       78.2 ± 8.8

  pCO~2~ (mmHg)                                                                      33.9 ± 4.0

  sO~2~ (%)                                                                          95.6 ± 2.2

  Cardiovascular risk factors, *n* (%)                                             

  Arterial hypertension                                                              11 (40.7%)

  Diabetes mellitus                                                                  4 (14.8%)

  Dyslipidaemia                                                                      12 (44.4%)

  Obesity                                                                            9 (33.3%)

  BMI (kg/m^2^)                                                                      29.3 ± 6.4

  Familial disposition                                                               10 (37.0%)

  Continued nicotine consumption                                                     12 (44.4%)

  Pack‐years                                                                         6.0 ± 9.5

  Cardiac symptomatology, *n* (%)[a](#ehf212243-note-0004){ref-type="fn"}          

  Palpitation                                                                        15 (55.6%)

  Chest pain                                                                         15 (55.6%)

  Dizziness                                                                          10 (37.0%)

  Syncopal episodes                                                                   0 (0.0%)

  NYHA functional class, *n* (%)                                                   

  No limitations                                                                      1 (3.7%)

  I                                                                                  6 (22.2%)

  II                                                                                 14 (51.9%)

  III                                                                                5 (18.5%)

  IV                                                                                  1 (3.7%)

  Cardiovascular medication use at CMR re‐conduction, *n* (%)                      

  Beta‐blocker                                                                       8 (29.6%)

  Bisoprolol                                                                         5 (18.5%)

  Metoprolol                                                                          2 (7.4%)

  Carvedilol                                                                          1 (3.7%)

  ACE inhibitor                                                                      9 (33.3%)

  Angiotensin II receptor blocker                                                     1 (3.7%)

  Diuretics                                                                          9 (33.3%)

  Ivabradine                                                                          2 (7.4%)

  Amiodarone                                                                          1 (3.7%)

  Immunosuppressant use at CMR re‐conduction, *n* (%)                              

  Steroidal monotherapy                                                              10 (37.0%)

  Azathioprine, combined with steroids                                                2 (7.4%)

  Methotrexate, combined with steroids                                                1 (3.7%)

  Immunosuppressant use since the initial, CS‐confirming CMR conduction, *n* (%)   

  Steroidal monotherapy                                                              11 (40.7%)

  Azathioprine, combined with steroids                                               4 (14.8%)

  Methotrexate, combined with steroids                                                1 (3.7%)
  -----------------------------------------------------------------------------------------------

Data are presented as mean ± SD or total number and percentage (in parentheses), as appropriate.

ACE, angiotensin converting enzyme; BMI, body mass index; CMR, cardiovascular magnetic resonance; CS, cardiac sarcoidosis; DLco, diffusion capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in first second of expiration; IVC, inspiratory vital capacity; NYHA, New York Heart Association; pCO~2~, carbon dioxide partial pressure; pO~2~, oxygen partial pressure; R tot, total resistance; RV, residual volume; sO~2~, oxygen saturation; TLC, total lung capacity; VA, alveolar volume.

Symptomatology refers to any time occurrence since the initial, CS‐confirming CMR conduction.

Overall, study population showed a slight predominance of men (59.3%) and was middle aged (49.9 ± 11.8 years); all patients were of Caucasian origin. Histological confirmation and principal manifestation of sarcoidosis were mainly pulmonary (55.6%). Pulmonary function testing revealed no substantial restrictive pattern, with values for inspiratory vital and total lung capacity within the normal range (94.4 ± 15.8% and 96.0 ± 11.5% of predicted, respectively). Mean diffusing capacity for carbon monoxide showed no restriction for pulmonary gas exchange (diffusion capacity of the lung for carbon monoxide/alveolar volume, 88.6 ± 14.2% of predicted). *Table* [1](#ehf212243-tbl-0001){ref-type="table-wrap"} presents the patients\' cardiovascular risk profile; of note, no patient had a history of concomitant coronary heart disease. Eight patients were asymptomatic for cardiac symptomatology that comprised chest pain, palpitations, dizziness, and syncopal episodes. At the time of CMR re‐conduction, 13 patients (48.1%) were under medical immunosuppressive treatment: 37.0% received steroidal monotherapy; in 7.4% and 3.7% of cases, azathioprine and methotrexate were added, respectively. Out of these 13 patients, in four patients, medical immunosuppressive treatment was primarily due to cardiac sarcoid affection, whereas the remaining nine patients received immunosuppressants in consequence of their extracardiac sarcoid manifestation.

Results obtained by cardiovascular magnetic resonance imaging {#ehf212243-sec-0015}
-------------------------------------------------------------

Presence of LGE defined cardiac sarcoid affection; early relative gadolinium enhancement and regional oedema were suspective of cardiac sarcoid involvement. Overall, aforesaid CMR findings were present in 14 out of 27 patients (51.9%). Differentiation of these persistently CS‐positive patients as a function of the disease\'s activity showed that 50.0% of patients had chronic, non‐viable‐fibrotic changes as described by LGE (*Figures* [1](#ehf212243-fig-0001){ref-type="fig"} and [2](#ehf212243-fig-0002){ref-type="fig"}): 7.1% of patients presented isolated acute inflammatory changes, suspective of sarcoidal origin, and 42.9% of patients presented both acute and chronic cardiac lesions. Localization analysis of late contrast enhancement per segment identified the mid‐inferoseptal ventricular region to be preferentially affected (*Table* [2](#ehf212243-tbl-0002){ref-type="table-wrap"}). *Table* [3](#ehf212243-tbl-0003){ref-type="table-wrap"} displays results obtained for LGE, early relative gadolinium enhancement, and T2‐weighted imaging at baseline and follow‐up CMR for the whole study population.

![CMR baseline (A, B) and follow‐up examination (C, D) in axial (A), horizontal long axis (C), and short axis orientation (B, D) in an asymptomatic patient without abnormalities in standard clinical testing. CMR demonstrates mid‐myocardial and subepicardial late gadolinium enhancement within the septal wall (arrows). Data correspond to Case 14 in *Table* [3](#ehf212243-tbl-0003){ref-type="table-wrap"}. CMR, cardiac magnetic resonance.](EHF2-5-249-g001){#ehf212243-fig-0001}

![CMR, ^68^Ga‐DOTATOC PET/CT, and ^68^Ga‐DOTATOC PET/CMR fused images (from left to right) of a 48‐year‐old woman with histologically proven pulmonary sarcoidosis and previously CMR‐confirmed cardiac affection. Follow‐up CMR illustrates mid‐myocardial oedema (full‐line arrow) alongside the mid‐ventricular anteroseptal myocardium and mid‐myocardial/subepicardial late gadolinium enhancement (dotted‐line arrow) at the mid‐ventricular septal level. Radionuclide imaging visualizes the highest focal ^68^Ga‐DOTATOC uptake alongside the mid‐anteroseptal myocardium (red asterisk). CMR, cardiovascular magnetic resonance; Gd, gadolinium; HLA, horizontal long axis; PET, positron emission tomography; T1w, T1 weighted; T2w, T2 weighted; VLA, vertical long axis.](EHF2-5-249-g002){#ehf212243-fig-0002}

###### 

Cardiac magnetic resonance‐derived cardiac functional parameters and dimensions, pathology\'s activity, and its localization

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                            All patients\    CMR‐based diagnosis of cardiac sarcoidosis[a](#ehf212243-note-0007){ref-type="fn"}\  CMR‐based exclusion of cardiac sarcoidosis\   *P*‐value
                                                                                                                                                            *n* = 27                                              *n* = 14                                        *n* = 13                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ------------------------------------------------------------------------------------- --------------------------------------------- -----------
  CMR‐assessed cardiac functional parameters and dimensions                                                                                                                                                                                                                                                     

  LVEF (%)                                                                                                                                                  58.8 ± 10.3                                          57.0 ± 11.4                                      60.7 ± 9.0                                    0.36

  LVEDV (mL)                                                                                                                                                141.8 ± 48.5                                        150.1 ± 59.2                                      132.9 ± 33.6                                  0.37

  IVSD (mm)                                                                                                                                                 9.8 ± 1.6                                             9.5 ± 1.4                                       10.3 ± 1.7                                    0.20

  CMR‐assessed pathology\'s activity, *n* (%)                                                                                                                                                                                                                                                                   

  Only non‐viable tissue damage, as assessed by late gadolinium enhancement                                                                                 7 (50.0%)                                                                                                                                           

  Both acute inflammatory and non‐viable tissue damage, as assessed by early relative gadolinium enhancement, T2 imaging, and late gadolinium enhancement   6 (42.9%)                                                                                                                                           

  Only acute inflammatory tissue damage, as assessed by early relative gadolinium enhancement                                                               1 (7.1%)                                                                                                                                            

  CMR‐assessed localization of LGE according to AHA\'s segmentation and nomenclature,[19](#ehf212243-bib-0019){ref-type="ref"} *n* (%)                                                                                                                                                                          

  1 basal anterior                                                                                                                                          3 (8.3%)                                                                                                                                            

  2 basal anteroseptal                                                                                                                                      3 (8.3%)                                                                                                                                            

  3 basal inferoseptal                                                                                                                                      3 (8.3%)                                                                                                                                            

  4 basal inferior                                                                                                                                          2 (5.6%)                                                                                                                                            

  5 basal inferolateral                                                                                                                                     3 (8.3%)                                                                                                                                            

  6 basal anterolateral                                                                                                                                     2 (5.6%)                                                                                                                                            

  7 mid‐anterior                                                                                                                                            4 (11.1%)                                                                                                                                           

  8 mid‐anteroseptal                                                                                                                                        4 (11.1%)                                                                                                                                           

  9 mid‐inferoseptal                                                                                                                                        5 (13.9%)                                                                                                                                           

  10 mid‐inferior                                                                                                                                           0 (0.0%)                                                                                                                                            

  11 mid‐inferolateral                                                                                                                                      2 (5.6%)                                                                                                                                            

  12 mid‐anterolateral                                                                                                                                      4 (11.1%)                                                                                                                                           

  13 apical anterior                                                                                                                                        1 (2.8%)                                                                                                                                            

  14 apical septal                                                                                                                                          0 (0.0%)                                                                                                                                            

  15 apical inferior                                                                                                                                        0 (0.0%)                                                                                                                                            

  16 apical lateral                                                                                                                                         0 (0.0%)                                                                                                                                            

  17 apex                                                                                                                                                   0 (0.0%)                                                                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are presented as mean ± SD or total number and percentage (in parentheses), as appropriate.

AHA, American Heart Association; CMR, cardiovascular magnetic resonance; IVSD, diastolic interventricular septal thickness; LGE, late gadolinium enhancement; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction.

Detection of cardiac sarcoidosis relied on presence of LGE; in case of early relative gadolinium enhancement or pathological T2‐weighted imaging, cardiac sarcoid involvement was suspected.

###### 

Results obtained for late gadolinium enhancement, early relative gadolinium enhancement, and T2‐weighted imaging at baseline and follow‐up cardiac magnetic resonance

  Case   Age   CMR baseline T2/rel. Enh/LGE   CMR follow‐up T2/rel. Enh/LGE    Immunosuppressant use since baseline CMR
  ------ ----- ------------------------------ ------------------------------- ------------------------------------------
  1      59    pos/neg/pos                    neg/neg/neg                                        pos
  2      55    neg/pos/neg                    neg/neg/neg                                        pos
  3      47    neg/pos/neg                    neg/neg/neg                                        neg
  4      42    neg/pos/neg                    neg/neg/neg                                        pos
  5      50    neg/pos/neg                    pos/pos/pos                                        pos
  6      47    neg/pos/neg                    neg/neg/neg                                        pos
  7      62    neg/pos/neg                    neg/neg/neg                                        pos
  8      46    neg/pos/neg                    neg/neg/neg                                        neg
  9      58    neg/neg/pos                    neg/neg/pos                                        neg
  10     25    neg/neg/pos                    neg/neg/pos                                        pos
  11     52    neg/neg/pos                    neg/neg/pos                                        neg
  12     52    neg/neg/pos                    neg/neg/pos                                        pos
  13     31    neg/neg/pos                    neg/neg/pos                                        pos
  14     61    neg/neg/pos                    neg/neg/pos                                        pos
  15     51    neg/pos/neg                    neg/pos/neg                                        neg
  16     47    neg/neg/pos                    neg/neg/pos                                        neg
  17     67    neg/pos/neg                    neg/neg/neg                                        pos
  18     50    pos/neg/neg                    neg/neg/neg                                        neg
  19     61    pos/neg/neg                    pos/neg/pos                                        neg
  20     22    neg/neg/pos                    pos/neg/pos                                        neg
  21     47    pos/neg/neg                    pos/neg/pos                                        neg
  22     51    neg/neg/pos                    neg/neg/neg                                        pos
  23     42    neg/neg/pos                    neg/neg/neg                                        pos
  24     37    pos/pos/neg                    pos/pos/pos                                        pos
  25     71    pos/pos/neg                    pos/neg/pos                                        pos
  26     54    neg/neg/pos                    neg/neg/neg                                        pos
  27     65    pos/neg/neg                    neg/neg/neg                                        neg

CMR, cardiovascular magnetic resonance; LGE, late gadolinium enhancement; neg, negative; pos, positive; rel. Enh, early relative gadolinium enhancement; T2, T2‐weighted imaging.

The comparison of CMR‐assessed left ventricular functional parameters and dimensions in CS‐positive and CS‐negative patients is displayed in *Table* [2](#ehf212243-tbl-0002){ref-type="table-wrap"}. Overall, mean values for left ventricular ejection fraction (LVEF), left ventricular end‐diastolic volume, and diastolic interventricular septal thickness were within the normal range (58.8 ± 10.3%, 141.8 ± 48.5 mL, and 9.8 ± 1.6 mm, respectively). None of the aforementioned CMR‐derived parameters differed significantly between CS‐positive and CS‐negative patients (*P* = 0.36, *P* = 0.37, and *P* = 0.20, respectively).

*Table* [3](#ehf212243-tbl-0003){ref-type="table-wrap"} displays CMR baseline and CMR follow‐up data. Remission of early relative enhancement or regional oedema was observed in seven cases, of which five patients were under immunosuppressive treatment since baseline CMR. Case 1 is visualized in *Figure* [*3*](#ehf212243-fig-0003){ref-type="fig"}: interestingly, former positive LGE, T2, and early relative gadolinium enhancement were not detectable in CMR follow‐up examination. This patient was under immunosuppressants since baseline CMR. This course is consistent with the observations made by Nagai *et al*. who reported a similar case with remission of LGE findings under immunosuppressive treatment.[21](#ehf212243-bib-0021){ref-type="ref"}

![Baseline CMR (A, C) and 6 month follow‐up (B, D) of a 59‐year‐old cardiac asymptomatic patient. This woman suffered from hepatic sarcoidosis that had been histologically proven by liver biopsy. The initial LGE image in short axis view shows a striatal mid‐myocardial enhancement within the basal inferior wall (A) with corresponding oedema in the T2 black‐blood image (C). Both LGE (B) and oedema (D) were not detectable within the follow‐up examination. Data correspond to those of Case 1 in *Table* [3](#ehf212243-tbl-0003){ref-type="table-wrap"}. CMR, cardiovascular magnetic resonance; LGE, late gadolinium enhancement.](EHF2-5-249-g003){#ehf212243-fig-0003}

Association of standard clinical testing parameters with cardiac magnetic resonance results {#ehf212243-sec-0016}
-------------------------------------------------------------------------------------------

*Table* [4](#ehf212243-tbl-0004){ref-type="table-wrap"} summarizes the distribution of standard evaluation parameters as a function of follow‐up CMR results. Conventional transthoracic echocardiography failed to recognize CS persistence. Neither reduction in LVEF \< 40% (enlisted as a diagnostic criterion within the current HRS expert consensus statement[12](#ehf212243-bib-0012){ref-type="ref"}) nor regional wall motion abnormalities or wall thickening (as specified by the revised JMHWG[13](#ehf212243-bib-0013){ref-type="ref"}) showed significant distributive differences between persistently CS‐positive and CS‐negative patients.

###### 

Demographic and clinical data, as a function of results at cardiac magnetic resonance re‐conduction

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                            All patients\     CMR‐based diagnosis of cardiac sarcoidosis[a](#ehf212243-note-0011){ref-type="fn"}\   CMR‐based exclusion of cardiac sarcoidosis\   *P*‐value
                                                                            *n* = 27          *n* = 14                                                                              *n* = 13                                      
  ------------------------------------------------------------------------- ----------------- ------------------------------------------------------------------------------------- --------------------------------------------- -----------
  Age (years)                                                               49.9 ± 11.8       48.8 ± 15.0                                                                           51.2 ± 7.4                                    0.60

  Male gender, *n* (%)                                                      16 (59.3%)        7 (50.0%)                                                                             9 (69.2%)                                     0.31

  Cardiac symptomatology, *n* (%)[b](#ehf212243-note-0012){ref-type="fn"}                                                                                                                                                         

  Palpitation                                                               15 (55.6%)        6 (42.9%)                                                                             9 (69.2%)                                     0.17

  Chest pain                                                                15 (55.6%)        6 (46.2%)                                                                             9 (69.2%)                                     0.23

  Dizziness                                                                 10 (37.0%)        4 (30.8%)                                                                             6 (46.2%)                                     0.42

  Syncopal episodes                                                         0 (0.0%)          0 (0.0%)                                                                              0 (0.0%)                                      

  NYHA functional class, *n* (%)                                                                                                                                                                                                  

  No limitations                                                            1 (3.7%)          1 (7.1%)                                                                              0 (0.0%)                                      0.33

  I                                                                         6 (22.2%)         4 (28.6%)                                                                             2 (15.4%)                                     0.41

  II                                                                        14 (51.9%)        5 (35.7%)                                                                             9 (69.2%)                                     0.08

  III                                                                       5 (18.5%)         3 (21.4%)                                                                             2 (15.4%)                                     0.69

  IV                                                                        1 (3.7%)          1 (7.1%)                                                                              0 (0.0%)                                      0.33

  Laboratory parameters                                                                                                                                                                                                           

  Leucocytes, g/L                                                           7.0 ± 2.3         6.8 ± 2.7                                                                             7.2 ± 1.9                                     0.62

  Haemoglobin, g/dL                                                         14.3 ± 1.2        14.2 ± 1.3                                                                            14.4 ± 1.2                                    0.67

  Thrombocytes, g/L                                                         255.4 ± 66.6      251.1 ± 53.4                                                                          260.2 ± 80.4                                  0.74

  C‐reactive protein, mg/dL                                                 4.4 ± 5.4         4.0 ± 6.1                                                                             4.9 ± 4.9                                     0.70

  sIL‐2R, U/mL                                                              838.6 ± 621.0     723.1 ± 354.7                                                                         973.3 ± 831.2                                 0.32

  ACE, U/L                                                                  39.2 ± 30.7       36.9 ± 30.2                                                                           41.6 ± 32.3                                   0.70

  NT‐proBNP, pg/mL                                                          110.7 ± 152.0     64.9 ± 32.0                                                                           153.00 ± 203.1                                0.15

  Pulmonary function parameters                                                                                                                                                                                                   

  FEV1 (L)                                                                  3.0 ± 1.0         3.0 ± 1.1                                                                             3.2 ± 1.0                                     0.56

  FEV1 (% predicted)                                                        92.9 ± 19.3       89.6 ± 19.8                                                                           97.9 ± 18.9                                   0.28

  RV (L)                                                                    2.1 ± 0.5         2.2 ± 0.6                                                                             2.0 ± 0.4                                     0.32

  RV (% predicted)                                                          105.6 ± 22.1      110.4 ± 26.7                                                                          99.1 ± 15.3                                   0.20

  R tot (kPa·s/L)                                                           0.24 ± 0.10       0.2 ± 0.1                                                                             0.3 ± 0.1                                     0.06

  R tot (% predicted)                                                       79.2 ± 35.1       67.1 ± 23.4                                                                           92.9 ± 40.0                                   0.06

  IVC (L)                                                                   3.9 ± 1.2         3.8 ± 1.1                                                                             4.0 ± 1.2                                     0.62

  IVC (% predicted)                                                         94.4 ± 15.8       92.6 ± 17.3                                                                           97.3 ± 14.2                                   0.46

  TLC (L)                                                                   6.0 ± 1.3         6.0 ± 1.2                                                                             6.0 ± 1.5                                     0.96

  TLC (% predicted)                                                         96.0 ± 11.5       96.7 ± 11.5                                                                           95.6 ± 11.5                                   0.82

  DLco (mmol/min/kPa)                                                       7.0 ± 2.2         6.7 ± 2.0                                                                             7.4 ± 2.3                                     0.43

  DLco (% predicted)                                                        72.6 ± 15.4       69.7 ± 14.9                                                                           76.6 ± 15.4                                   0.26

  DLco/VA (mmol/min/kPa/L)                                                  1.4 ± 0.2         1.3 ± 0.2                                                                             1.4 ± 0.2                                     0.37

  DLco/VA (% predicted)                                                     88.6 ± 14.2       86.0 ± 14.0                                                                           91.7 ± 14.0                                   0.31

  Capillary blood gas analysis                                                                                                                                                                                                    

  pO~2~ (mmHg)                                                              78.2 ± 8.8        78.1 ± 7.7                                                                            78.3 ± 10.2                                   0.95

  pCO~2~ (mmHg)                                                             33.9 ± 4.0        34.5 ± 2.8                                                                            33.2 ± 5.0                                    0.42

  sO~2~ (%)                                                                 95.6 ± 2.2        95.93 ± 0.9                                                                           95.3 ± 3.0                                    0.61

  Echocardiographic pathologies, *n* (%)                                                                                                                                                                                          

  LVEF \< 40%                                                               3 (10.3%)         3 (21.4%)                                                                             0 (0.0%)                                      0.09

  LVEDV (mL)                                                                116.9 ± 66.1      130.4 ± 85.6                                                                          101.0 ± 27.2                                  0.29

  Diastolic dysfunction ≥ *I*°                                              13 (48.1%)        7 (50.0%)                                                                             6 (54.5%)                                     0.82

  Regional abnormal wall motion                                             2 (7.4%)          1 (7.1%)                                                                              1 (8.3%)                                      0.91

  Wall thickening                                                           11 (40.7%)        7 (50.0%)                                                                             4 (33.3%)                                     0.39

  Ventricular aneurysm                                                      0 (0.0%)          0 (0.0%)                                                                              0 (0.0%)                                      

  Mitral valve regurgitation ≥ *I*°                                         16 (59.3%)        9 (64.3%)                                                                             7 (58.3%)                                     0.76

  ECG pathologies, *n* (%)                                                                                                                                                                                                        

  Heart rate (b.p.m.)                                                       72.2 ± 12.7       69.3 ± 12.7                                                                           75.0 ± 12.1                                   0.26

  Advanced atrioventricular block                                           2 (7.4%)          1 (7.1%)                                                                              1 (7.7%)                                      0.62

  Abnormal Q‐wave                                                           3 (11.1%)         1 (7.1%)                                                                              2 (15.4%)                                     0.32

  QRS fragmentation                                                         5 (18.5%)         2 (14.3%)                                                                             3 (23.1%)                                     0.34

  T‐wave negativity, *n* (%)                                                13 (48.1%)        7 (50.0%)                                                                             6 (46.2%)                                     0.31

  Complete RBBB                                                             0 (0.0%)          0 (0.0%)                                                                              0 (0.0%)                                      

  Incomplete LBBB                                                           2 (7.4%)          2 (14.3%)                                                                             0 (0.0%)                                      0.16

  Complete LBBB                                                             2 (7.4%)          1 (7.1%)                                                                              1 (7.7%)                                      0.62

  QTc interval duration (ms)                                                428.8 ± 33.5      423.2 ± 29.7                                                                          431.9 ± 36.8                                  0.52

  Premature atrial contractions                                             1 (3.7%)          1 (7.1%)                                                                              0 (0.0%)                                      0.33

  Premature ventricular contractions                                        3 (11.1%)         2 (14.3%)                                                                             1 (7.7%)                                      0.59

  Holter monitoring pathologies, *n* (%)                                                                                                                                                                                          

  Heart rate (b.p.m.)                                                       76.7 ± 10.1       73.4 ± 9.9                                                                            80.3 ± 9.5                                    0.11

  Premature atrial contractions                                             115.5 ± 230.4     137.8 ± 295.4                                                                         91.1 ± 139.9                                  0.64

  Atrial fibrillation                                                       0 (0%)            0 (0%)                                                                                0 (0%)                                        

  Premature ventricular contractions                                        659.6 ± 2207.4    1122.4 ± 3010.0                                                                       154.7 ± 464.6                                 0.30

  Sustained ventricular tachycardia                                         0 (0%)            0 (0%)                                                                                0 (0%)                                        

  T‐wave alternans                                                          15.2 ± 7.6        14.9 ± 8.3                                                                            15.6 ± 7.2                                    0.83

  Heart rate variability measures                                                                                                                                                                                                 

  Time‐domain analysis                                                                                                                                                                                                            

  SDNN (ms)                                                                 128.9 ± 36.5      131.2 ± 40.3                                                                          126.3 ± 33.6                                  0.76

  SDANN (ms)                                                                114.5 ± 32.0      116.6 ± 35.8                                                                          112.2 ± 28.9                                  0.75

  RMSSD (ms)                                                                26.1 ± 13.9       27.5 ± 13.4                                                                           24.6 ± 14.9                                   0.63

  PNN50%                                                                    5.9 ± 9.1         6.3 ± 8.2                                                                             5.5 ± 10.5                                    0.83

  Frequency‐domain analysis                                                                                                                                                                                                       

  HF (ms^2^)                                                                185.1 ± 246.9     219.8 ± 321.3                                                                         147.2 ± 132.1                                 0.49

  LF (ms^2^)                                                                647.2 ± 693.4     650.2 ± 861.7                                                                         643.9 ± 490.9                                 0.98

  VLF (ms^2^)                                                               2152.3 ± 1862.0   2458.5 ± 2418.8                                                                       1818.4 ± 978.1                                0.42

  LF/HF                                                                     4.6 ± 3.6         3.7 ± 2.7                                                                             5.6 ± 4.3                                     0.21

  Total power (ms^2^)                                                       2914.8 ± 2204.3   3065.8 ± 2772.9                                                                       2750.0 ± 1474.6                               0.74
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are presented as mean ± SD or total number and percentage (in parentheses), as appropriate.

ACE, angiotensin converting enzyme; b.p.m., beats per minute; CMR, cardiovascular magnetic resonance; DLco, diffusion capacity of the lung for carbon monoxide; ECG, electrocardiography; FEV1, forced expiratory volume in first second of expiration; HF, high frequency; IVC, inspiratory vital capacity; LBBB, left bundle branch block; LF, low frequency; LF/HF ratio, low frequency/high frequency ratio; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; NT‐proBNP, N terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association; pCO2, carbon dioxide partial pressure; PNN50%, percent NN intervals \>50 ms different from the prior interval; pO2, oxygen partial pressure; QTc, corrected QT; R tot, total resistance; RBBB, right bundle branch block; RMSSD; root‐mean square successive difference of R‐R intervals; RV, residual volume; SDANN, standard deviation of the average NN intervals; SDNN = mean standard deviation of NN intervals; sIL‐2R, soluble interleukin‐2 receptor; sO2, oxygen saturation; TLC, total lung capacity; VA, alveolar volume; VLF, very low frequency.

Detection of cardiac sarcoidosis relied on presence of late gadolinium enhancement; in case of early relative gadolinium enhancement or pathological T2‐weighted imaging, cardiac sarcoid involvement was suspected.

Symptomatology refers to any time occurrence since the initial, CS‐confirming CMR conduction.

In like manner, findings obtained by 12‐lead ECG, 24 h Holter monitoring, laboratory, and pulmonary function testing did not show correlation with CMR results. Cardiac symptomatology, as occurred in the period between the initial, CS‐confirming CMR, and the follow‐up examination, was balanced between groups and not indicative of CS degree or persistence.

Results obtained by ^68^ Ga‐DOTATOC positron emission tomography/computed tomography {#ehf212243-sec-0017}
------------------------------------------------------------------------------------

Observational data on ^68^Ga‐DOTATOC‐directed PET/CT imaging were available for 17 out of 27 followed‐up patients: Out of 17 patients who underwent PET/CT, five subjects presented acute inflammatory injury in CMR imaging (T2‐weighted imaging and early relative gadolinium enhancement). Out of these five patients, only one patient presented PET/CT pathologies: as depicted in *Figure* [*2*](#ehf212243-fig-0002){ref-type="fig"}, the highest focal ^68^Ga‐DOTATOC uptake correlated with the area of myocardial oedema.Further five out of 17 patients who underwent ^68^Ga‐DOTATOC PET/CT presented isolated LGE in CMR. All of them presented negative PET/CT findings. Out of these five patients, three subjects were under immunosuppressive treatment, while the remaining two patients offered less extensive LGE that only comprised one ventricular segment.[19](#ehf212243-bib-0019){ref-type="ref"}The remaining seven subjects were all CMR negative for CS and concordantly negative in PET/CT imaging.

Discussion {#ehf212243-sec-0018}
==========

The main findings of our study are as follows: (i) within a time frame of 2.6 years, cardiac sarcoid involvement persisted in barely half the patients, as confirmed by CMR re‐examination. (ii) Although two patients developed advanced heart block, no deaths occurred during follow‐up. (iii) ^68^Ga‐DOTATOC PET/CT revealed areas of increased tracer uptake to be consistent with acute inflamed myocardium. (iv) The diagnostic value of standard clinical testing, as recommended by the current agreements,[12](#ehf212243-bib-0012){ref-type="ref"}, [13](#ehf212243-bib-0013){ref-type="ref"} was found to be modest.

Over a median time interval of 2.6 years, Greulich and colleagues performed longitudinal follow‐up in a cohort that comprised 155 patients with systemic sarcoidosis and clinically suspected cardiac affection.[22](#ehf212243-bib-0022){ref-type="ref"} During this period, three patients died, and four patients experienced aborted sudden cardiac death among the CS population. Almost all of these events occurred for cardiac reasons and were best predicted by presence of LGE. Consistent with Greulich\'s trial, we presently performed CS patients\' follow‐up over a median period of 2.6 years. Although two of our 29 initially CS‐positive patients developed advanced heart block in the meantime, no deaths were registered. Thus, our results are contrary to Greulich\'s observations and relativize both the risk of CS persistence and the fatality that CS has been ascribed to. This discrepancy in event rates may foremost be originated by differences in study population selection: we consciously included all sarcoidal patients irrespective of any cardiac symptomatology at the time of baseline CMR study in terms of an actual screening for CS. Out of these original 188 sarcoidosis patients, CMR detected cardiac affection in 29 patients, 10 of which were clinically inapparent (with regard to chest pain, palpitations, dizziness, and syncopal episodes). At the time of CMR re‐conduction, eight out of 27 patients still did not present any clinical cardiac symptomatology. By contrast, Greulich and colleagues focused on patients with clinically suspected cardiac sarcoid affection. Likewise, Blankstein *et al*. related ^18^F‐fluorodeoxyglucose (^18^F‐FDG) PET/CT imaging findings to adverse events in 118 patients with clinical suspected or known CS during a follow‐up period of 1.5 years.[23](#ehf212243-bib-0023){ref-type="ref"} Adverse cardiac events (sustained ventricular tachycardia or death) were reported in 26% of study population, and abnormal PET/CT results were present in 60% of study population. This high number of adverse events may be ascribed to the pronounced clinical symptomatology of study population; e.g. 40% already had an implantable cardiac defibrillator prior to PET/CT, mean ejection fraction was 47 ± 16%, and JMHWG criteria turned positive in 34% of study population. In this line of thought, a recent review that included eight studies on prevalence and prognosis of clinically silent CS reported a more favourable course in clinical silent CS in five out of these eight studies: within a mean follow‐up of 23 months, no adverse cardiac event like ventricular arrhythmia or death was reported.[24](#ehf212243-bib-0024){ref-type="ref"} It illustrates that differences in cardiac symptomatology of study population may influence adverse events\' occurrence.

Detection of CS relied on presence of LGE; in case of early relative gadolinium enhancement and pathological T2‐weighted imaging, cardiac sarcoid involvement was suspected. The diagnostic value of myocardial T2 mapping to detect CS has been subject to prior studies. Crouser and colleagues conducted a retrospective study of 50 patients with histologically proven sarcoidosis that underwent CMR for suspected CS.[25](#ehf212243-bib-0025){ref-type="ref"} CMR results were compared with those obtained in 14 healthy control subjects. They observed a significantly elevated T2 in sarcoidosis patients as compared with controls. Moreover, LGE and T2 abnormalities did not always go hand in hand, suggesting complementary diagnostic information from both techniques to identify CS. They concluded that a comprehensive CMR approach to detect CS should include both T2‐weighted imaging and LGE.

As to early relative gadolinium enhancement, Schulz‐Menger *et al*. identified early relative contrast enhancement in patients with suspected cardiac sarcoidal involvement that normalized after glucocorticoid therapy.[18](#ehf212243-bib-0018){ref-type="ref"} In a population of 16 patients presenting systemic sarcoidosis, Shimada *et al*. detected early enhancing lesions that were likewise remitting under steroid treatment.[26](#ehf212243-bib-0026){ref-type="ref"} Both studies illustrate the value of early local and global contrast enhancement in viable myocardium that may mainly occur in early CS stages. In equal manner to the above depicted courses, we observed remission of early relative enhancement under immunosuppressive treatment in five cases, implying remission of early stage CS.

Additional complexity emerges from the value of standard clinical testing. Despite being enlisted in the current agreement papers,[12](#ehf212243-bib-0012){ref-type="ref"}, [13](#ehf212243-bib-0013){ref-type="ref"} electrical recording and conventional echocardiography failed to be indicative of CS: application of the HRS consensus recommendations on ECG, Holter monitoring, and echocardiography would have enabled us to solely diagnose three out of 14 CS cases. In addition to established CS diagnostic criteria, we examined heart rate variability and T‐wave alternans as general risk stratifiers for sudden cardiac death by influencing the onset and sustainment of malignant ventricular arrhythmias.[11](#ehf212243-bib-0011){ref-type="ref"}, [27](#ehf212243-bib-0027){ref-type="ref"}, [28](#ehf212243-bib-0028){ref-type="ref"} Neither comparison of persistently CS‐positive with CS‐negative patients nor comparison of PET‐positive with PET‐negative patients revealed significantly different values of the aforementioned risk stratifiers. This finding is consistent with the presently observed lack in sustained ventricular tachycardia and points at a more favourable CS course and prognosis.

A more sophisticated imaging tool for evaluating patients with suspected or confirmed CS arises from radionuclide approaches. Among these, gallium scintigraphy and ^18^F‐FDG PET/CT represent the best‐studied techniques, with the latter offering a higher sensitivity than single photon‐emitting procedures.[29](#ehf212243-bib-0029){ref-type="ref"} SSTR‐directed PET/CT has been demonstrated to be feasible for imaging atherosclerotic and myocardial inflammatory processes.[10](#ehf212243-bib-0010){ref-type="ref"}, [30](#ehf212243-bib-0030){ref-type="ref"} The potential of SSTR‐directed PET/CT in the field of granulomatous diseases has foremost been described for ^111^In‐labelled octreotide.[31](#ehf212243-bib-0031){ref-type="ref"}

We performed ^68^Ga‐DOTATOC PET/CT instead of ^18^F‐FDG PET/CT in consequence of the limitations that FDG entails: specificity of FDG PET/CT is hampered by the need for dedicated patient preparation that otherwise may limit its diagnostic value.[32](#ehf212243-bib-0032){ref-type="ref"} By contrast, ^68^Ga‐DOTATOC PET/CT overcomes this disadvantage: as the fasting preparation protocol is less rigorous, the rate of adequately prepared patients and consequently the procedure\'s validity are higher. Moreover, a shorter examination time and lower radiation exposure favour SSTR imaging.

However, the use of the SSTR ligand ^68^Ga‐DOTATOC for the evaluation of CS is limited to a study by Lapa *et al*.[33](#ehf212243-bib-0033){ref-type="ref"} and a case report by Reiter *et al*.[34](#ehf212243-bib-0034){ref-type="ref"} Lapa and colleagues compared SSTR‐PET/CT and CMR imaging findings in 15 patients with biopsy‐proven CS or extra‐CS and clinical suspicion on cardiac involvement. SSTR‐PET/CT and CMR imaging were concordantly in 79.3% of all CMR positive segments (23/29 segments), and an overall concordance of 96.1% of all segments (245/255) was described. In three cases, PET/CT and CMR results differed (negative PET/CT results vs. positive CMR results); two of these three patients were under immunosuppressants, and the remaining one was missed owing to minor wall involvement in CMR (\<25% of wall thickness). None of the PET/CT positive patients were under immunosuppressive treatment at PET/CT conduction.

Reiter *et al*. also described concordance of CMR‐stated and ^68^Ga‐DOTATOC PET/CT‐stated acute myocardial damage in a case report with histologically proven extra‐CS and a response of cardiac involvement after systemic glucocorticoid therapy.[34](#ehf212243-bib-0034){ref-type="ref"}

We presently identified one patient with pathologically increased radiotracer uptake; the hereby visualized myocardial localization corresponded to cardiac areas of acute inflammation. This observation is consistent with the tracer\'s biodistribution that can be deduced from its binding profile: as the SSTR is overexpressed on activated macrophages, lymphocytes, and epithelioid cells, specific SSTR‐targeted radiotracers like ^68^Ga‐DOTATOC may directly display their distribution and thereby identify sites of inflammation.[10](#ehf212243-bib-0010){ref-type="ref"}, [35](#ehf212243-bib-0035){ref-type="ref"} By contrast, LGE primarily depicts myocardial scar; given the aforesaid biodistribution of ^68^Ga‐DOTATOC, PET/CT presently failed at imaging CMR‐detected LGE.

Overall, among the 17 patients of our study population for whom PET/CT data were available, CMR‐based T2 imaging and early relative gadolinium enhancement detected acute inflammatory injury in five patients; out of these five patients, only one patient with abnormal T2 finding presented PET/CT pathologies. This discrepancy may be ascribed to the medication use at the time of radionuclide imaging: whereas the aforementioned PET/CT‐positive patient did not receive immunosuppressants at the time of PET/CT conduction, the remaining four patients were under immunosuppressive medication. This finding is consistent with the observation made by Lapa *et al*.[33](#ehf212243-bib-0033){ref-type="ref"}: ^68^Ga‐DOTATOC PET/CT detected acute inflammatory processes in patients not receiving immunosuppressants. Therefore, ^68^Ga‐DOTATOC PET/CT may be a useful tool to monitor diseases\' activity under immunosuppressive therapy especially in patients with contraindications to CMR like device therapy or renal impairment. Nonetheless, given that only one patient presented PET/CT pathologies, future studies are warranted to definitely determine the value of SSTR scintigraphy as imaging modality for evaluation of CS activity and for following response to treatment.

There are several limitations that should be addressed. First, the non‐randomized and single‐centred study design may have affected our data through procedure bias. As we performed follow‐up of previously diagnosed CS patients, the study population size was modest, and the chosen time frame of 2.6 years may have been too short to properly assess patients\' outcome, as the number of events resulted to be low. In consequence of the limited sample size, adjustment for pre‐existing clinical symptomatology, medical treatment, and size of CMR‐detected lesions was not feasible and might mitigate the study\'s conclusion on prognosis in CS. In keeping with this, longer‐termed follow‐up would have enabled us to additionally address the predictive value of PET/CT findings. Finally, as PET/CT data were retrospectively extracted, a prospective approach examining the diagnostic impact of ^68^Ga‐DOTATOC PET/CT, especially in comparison with ^18^F‐FDG PET/CT, would be of additional value.

In conclusion, in our CS‐positive study population, cardiac sarcoid affection persisted in barely half the patients after a period of 2 years, and the patients were not afflicted with cardiac death. It points at minor diseases\' perseverance and at a more favourable disease\'s course. ^68^Ga‐DOTATOC PET/CT imaging allowed for visualization of acute myocardial inflammation. However, to definitively determine its value in CS imaging, future studies are warranted.
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